Sublingual sugar for hypoglycaemia in children with severe malaria: A pilot clinical study

Malaria Journal

Table 2 Intention to treat analysis: Clinical and biological responses to IV glucose or sublingual sugar administration among children with hypoglycaemia (BGC < 60 mg/dl) in Mali

	Sublingual Sugar (SLS)	Intravenous Glucose (IVG)	p
	n = 14 (95%CI)	n = 9 (95%CI)
Primary Outcome measure
- Treatment Response (reaching 60 mg within 40 minutes)	10/14 (71%)	6/9 (67%)	0.81
Secondary outcome measures
- Early treatment response^a	9/14 (64.3%)	6/9 (67%)	0.91
- Relapse^b (as % of treatment responders)	3/10 (30%)	1/6 (17%)	0.55
-CGmax^d(mg/dl)	43.4 (25.8–62.5)	46.2 (19.1–73.2)	0.60
-Treatment delay (mins)^e	< 5	18.9 (6.4–31.6)	-
Case Fatality	1 (7%)	1 (11%)	NS

^a defined as a significant blood glucose gain (> 10 mg/dl) at or before 20 minutes
^b defined as children who reached a normal glycaemia 3.3 mmol/L (60 mg/dl), but failed to maintain it
^c defined as the difference between baseline BGC and the peak glucose concentration (on the first-line treatment) within the first 40 minutes
^d the time from confirmation of hypoglycaemia to the beginning of treatment. Treatment delay for SLS was always less than 5 minutes and was not recorded precisely so 5 minutes was taken as a conservative estimate; for IVG, treatment delay was the observed value.

ISSN: 1475-2875